ArticleIntegrative medicine (Encinitas, Calif.)2025
Clinical Utility of Urine Hormone Metabolite Testing in Personalized Medicine: A Case Report of a Male Patient with Low Testosterone.
Article in Integrative medicine (Encinitas, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Customizing dietary supplementation for each patient based on biomarker testing could maximize a supplement's health benefits and minimize safety-related issues. This case report demonstrates an integrative provider's use of hormone testing to guide personalized supplement recommendations for their patient. Case Presentation: The patient was a healthy 47-year-old man who expressed interest in obtaining information about his testosterone levels. He underwent sex hormone testing using baseline serum measurement, as well as an at-home four-spot dried urine collection kit (DUTCH Test, Precision Analytical, Inc.) at baseline and before and after each intervention. Baseline serum free testosterone and urinary testosterone levels were at the low end of the age-dependent male reference range. Available genetic results also showed a catechol-O-methyltransferase (COMT) V158M polymorphism. The provider recommended human chorionic gonadotropin (HCG) to address low testosterone. Outcome: After HCG treatment, testosterone increased as desired. A simultaneous above-range increase in estradiol prompted the provider to recommend a supplement containing calcium D-glucarate (CDG) and diindolylmethane (DIM). While CDG+DIM normalized estradiol, it elevated 2-hydroxyestrone (2-OH-E1) and 4-hydroxyestradiol (4-OH-E2) above range. In addition, the ratio of 2-methoxyestrone (phase-2 estrogen metabolite) to 2-OH-E1 (phase-1 estrogen metabolite) continued to decline further with each intervention, indicating a reduced capacity for estrogen detoxification, possibly related to the patient's COMT variant. To improve methylation activity, trimethylglycine was added, which normalized the 2-methoxyestrone/2-OH-E1 ratio. Finally, sex hormone and metabolite levels were within range, without any adverse events. Discussion: Sex hormone and hormone metabolite testing before and after each intervention enabled careful step-by-step additions of supplements, which helped to improve testosterone levels while maintaining healthy estrogen metabolism. Given the patient's genetic background, this approach also ensured that any unintended effects on methylation were minimized. The convenience of the at-home dried urinary sampling method facilitated before-and-after testing.
Identifiers
41103795PMC12520245What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.